FI922142A0 - Enzymatisk resolution av endo- bicyklo/2.2.1/heptan-2-ol och daerav haerledda farmaceutiska aemnen. - Google Patents

Enzymatisk resolution av endo- bicyklo/2.2.1/heptan-2-ol och daerav haerledda farmaceutiska aemnen.

Info

Publication number
FI922142A0
FI922142A0 FI922142A FI922142A FI922142A0 FI 922142 A0 FI922142 A0 FI 922142A0 FI 922142 A FI922142 A FI 922142A FI 922142 A FI922142 A FI 922142A FI 922142 A0 FI922142 A0 FI 922142A0
Authority
FI
Finland
Prior art keywords
endo
resolution
haerledda
enzymatisk
aemnen
Prior art date
Application number
FI922142A
Other languages
English (en)
Other versions
FI105106B (fi
FI922142A (fi
Inventor
Nicholas A Saccomano
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI922142A0 publication Critical patent/FI922142A0/fi
Publication of FI922142A publication Critical patent/FI922142A/fi
Application granted granted Critical
Publication of FI105106B publication Critical patent/FI105106B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
FI922142A 1989-11-13 1992-05-12 Menetelmä optisesti aktiivisen (2S)-endo-bisyklo[2.2.1]heptan-2-olin tai (2R)-endo-bisyklo[2.2.1]heptan-2-olin valmistamiseksi ja menetelmässä käytettävät välituotteet FI105106B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8905228 1989-11-13
PCT/US1989/005228 WO1991007501A1 (en) 1989-11-13 1989-11-13 Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents

Publications (3)

Publication Number Publication Date
FI922142A0 true FI922142A0 (fi) 1992-05-12
FI922142A FI922142A (fi) 1992-05-12
FI105106B FI105106B (fi) 2000-06-15

Family

ID=22215375

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922142A FI105106B (fi) 1989-11-13 1992-05-12 Menetelmä optisesti aktiivisen (2S)-endo-bisyklo[2.2.1]heptan-2-olin tai (2R)-endo-bisyklo[2.2.1]heptan-2-olin valmistamiseksi ja menetelmässä käytettävät välituotteet

Country Status (27)

Country Link
EP (2) EP0428302B1 (fi)
JP (1) JPH06104661B2 (fi)
KR (1) KR930004654B1 (fi)
CN (1) CN1040423C (fi)
AT (1) ATE158577T1 (fi)
AU (3) AU633157B2 (fi)
CA (1) CA2029705C (fi)
CZ (2) CZ280006B6 (fi)
DE (1) DE69031487T2 (fi)
DK (1) DK0428302T3 (fi)
EG (1) EG19860A (fi)
ES (1) ES2107420T3 (fi)
FI (1) FI105106B (fi)
GR (1) GR3025196T3 (fi)
HU (2) HU215441B (fi)
IE (2) IE980174A1 (fi)
IL (5) IL110564A (fi)
MY (1) MY104517A (fi)
NO (1) NO304838B1 (fi)
NZ (1) NZ236037A (fi)
PH (1) PH30255A (fi)
PL (4) PL164202B1 (fi)
PT (1) PT95855B (fi)
RU (1) RU2104306C1 (fi)
WO (1) WO1991007501A1 (fi)
YU (1) YU48413B (fi)
ZA (1) ZA909044B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104306C1 (ru) * 1989-11-13 1998-02-10 Пфайзер Инк. Способ получения оптически активного (2s)- или (2r)-эндо-бицикло[2.2.1]гептан-2-ола, способ получения 5-(3-[(2r)-экзо-бицикло[2.2.1]гепт-2-илокси]-4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-она, оптически активный 5-(3-[экзо-бицикло[2.2.1]гепт-2-илокси]4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-он, оптически активные промежуточные соединения и способ их получения
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
NZ246087A (en) * 1991-12-06 1995-04-27 Shionogi Seiyaku Kk Production of optically active norborneol from a racemic ester mixture using a microoganism or treated cells thereof
DE69332762T2 (de) * 1992-12-02 2003-08-14 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
JP3431204B2 (ja) * 1993-04-22 2003-07-28 塩野義製薬株式会社 ノルボルナン型エステル・ヒドロラーゼ
CN1041436C (zh) * 1993-05-07 1998-12-30 佛山市制药一厂 一种稳定冯了性风湿跌打药酒的方法
US5482944A (en) * 1993-07-13 1996-01-09 Pfizer Inc. Pyrimidones and imidazolinones for treatment of shock
WO2001013953A2 (en) 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
JPH1142095A (ja) * 1997-07-25 1999-02-16 Chisso Corp 新規なオキソジシクロペンタジエンの製造方法
KR100479019B1 (ko) * 1998-05-22 2005-08-29 씨제이 주식회사 캐테콜히드라존유도체,이의제조방법및그를함유한약제학적조성물
KR20040017246A (ko) 2001-06-29 2004-02-26 니켄 가가쿠 가부시키가이샤 사이클로알케논 유도체
ES2194588B1 (es) * 2001-07-13 2004-10-16 Astur Pharma S.A. Precursores opticamente puros de paroxetina.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2681236B1 (en) 2011-03-01 2018-01-03 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261995A (en) * 1979-08-31 1981-04-14 Syntex (U.S.A.) Inc. 4-Phenyl-and 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives
US4732853A (en) * 1984-11-21 1988-03-22 President And Fellows Of Harvard College Method of making chiral epoxy alcohols
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
RU2104306C1 (ru) * 1989-11-13 1998-02-10 Пфайзер Инк. Способ получения оптически активного (2s)- или (2r)-эндо-бицикло[2.2.1]гептан-2-ола, способ получения 5-(3-[(2r)-экзо-бицикло[2.2.1]гепт-2-илокси]-4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-она, оптически активный 5-(3-[экзо-бицикло[2.2.1]гепт-2-илокси]4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-он, оптически активные промежуточные соединения и способ их получения

Also Published As

Publication number Publication date
JPH06104661B2 (ja) 1994-12-21
CZ124092A3 (en) 1995-04-12
JPH03173871A (ja) 1991-07-29
IL110568A0 (en) 1994-11-11
CZ280006B6 (cs) 1995-09-13
DK0428302T3 (da) 1997-10-13
YU214290A (sh) 1992-12-21
GR3025196T3 (en) 1998-02-27
CZ280011B6 (cs) 1995-09-13
WO1991007501A1 (en) 1991-05-30
ATE158577T1 (de) 1997-10-15
HU215441B (hu) 1999-04-28
EP0428302A3 (en) 1992-05-13
FI105106B (fi) 2000-06-15
PH30255A (en) 1997-02-05
CZ560990A3 (en) 1995-04-12
MY104517A (en) 1994-04-30
HUT64604A (en) 1994-01-28
IL110564A (en) 1998-03-10
AU3292093A (en) 1993-04-22
IL110568A (en) 1995-10-31
RU2104306C1 (ru) 1998-02-10
PT95855B (pt) 1998-01-30
PL164202B1 (pl) 1994-06-30
EG19860A (en) 1996-03-31
KR910009622A (ko) 1991-06-28
PL164176B1 (pl) 1994-06-30
IE904059A1 (en) 1991-05-22
ES2107420T3 (es) 1997-12-01
IE980174A1 (en) 2000-02-23
YU48413B (sh) 1998-07-10
PL292070A1 (en) 1992-04-21
PL165132B1 (pl) 1994-11-30
AU645449B2 (en) 1994-01-13
NO921876L (no) 1992-07-10
IL110564A0 (en) 1994-11-11
FI922142A (fi) 1992-05-12
EP0428302B1 (en) 1997-09-24
PL164457B1 (pl) 1994-07-29
NZ236037A (en) 1992-08-26
HU9802988D0 (en) 1999-11-29
NO304838B1 (no) 1999-02-22
DE69031487T2 (de) 1998-02-05
EP0801135A1 (en) 1997-10-15
PL287727A1 (en) 1992-02-24
CA2029705A1 (en) 1991-05-14
KR930004654B1 (ko) 1993-06-02
DE69031487D1 (de) 1997-10-30
CA2029705C (en) 1998-11-24
PL292069A1 (en) 1992-04-21
CN1040423C (zh) 1998-10-28
AU633157B2 (en) 1993-01-21
ZA909044B (en) 1992-06-24
NO921876D0 (no) 1992-05-12
IL96261A0 (en) 1991-08-16
AU3197993A (en) 1993-04-22
HU220962B1 (hu) 2002-07-29
AU6653590A (en) 1991-05-16
CN1051905A (zh) 1991-06-05
IL96261A (en) 1996-12-05
EP0428302A2 (en) 1991-05-22
PT95855A (pt) 1991-09-13

Similar Documents

Publication Publication Date Title
FI922142A (fi) Enzymatisk resolution av endo- bicyklo/2.2.1/heptan-2-ol och daerav haerledda farmaceutiska aemnen.
FI892313A (fi) Menetelmä tasolasin tai tasolasituotteiden optisen laadun määräämistä varten
FI895228A0 (fi) Integrerad optisk anordning foer maetning av brytningsindex hos vaetskan.
AU6881791A (en) Mammalian pancreatic cholesterol esterase
FI990018A0 (fi) Elektronisuihkun pyyhkäisynopeuden modulointilaite
AU4008589A (en) Optical beam scanning apparatus
AU580668B2 (en) A new process for the optical resolution of racemic mixtures of ``-naphthylpropionic acids
DK164060C (da) Fremgangsmaade til fremstilling af 7-amino-3-alkoxymethyl-3-cephem-4-carboxylsyrer samt fremgangsmaade til fremstilling af et 7-acyleret cephalosporin-antibiotikum ved acylering af en saadan 7-amino-3-alkoxymethyl-3-cephem-4-carboxylsyre
EP0728708A3 (en) Method of manufacturing a stable polarized optical fiber
FI904389A0 (fi) Anordning och foerfarande foer reducering av distortion i ett analogt optiskt transmisonssystem.
DK312988A (da) Fremgangsmaade til fremstilling af zidovudin samt mellemprodukter ved fremgangsmaaden
FI890425A (fi) Metod foer optisk datalagring och material foer denna.
CS829588A2 (en) Telecentric optical system of objective for wobbled laser beam focusing
GB9011302D0 (en) Novel techniques for the fabrication of optical microstructures
GB9001972D0 (en) Novel techniques for the fabrication of optical microstructures
DK33189D0 (da) Apparat til fremvisning af hastigheden for et koeretoej
CS396287A1 (en) Method of display on laser's focusing screen

Legal Events

Date Code Title Description
MA Patent expired